Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN ESTOLATE versus WYAMYCIN S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN ESTOLATE versus WYAMYCIN S.
ERYTHROMYCIN ESTOLATE vs WYAMYCIN S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin estolate is a macrolide antibiotic that reversibly binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step. It may also exhibit immunomodulatory and anti-inflammatory effects.
WYAMYCIN S (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
250-500 mg orally every 6-12 hours
WYAMYCIN S (clarithromycin/sulfamethoxazole) is a fixed-dose combination. Adult: 1 tablet (500 mg clarithromycin/800 mg sulfamethoxazole) orally every 12 hours for 7-14 days.
None Documented
None Documented
Approximately 1.5-2 hours in normal adults; prolonged to 5-6 hours in end-stage renal disease.
2-3 hours in normal renal function; prolonged to 24-48 hours in end-stage renal disease.
Primarily hepatic via biliary excretion into feces; approximately 2-5% excreted unchanged in urine. <5% renal elimination.
Renal (90-95% unchanged via glomerular filtration) and biliary (<5%).
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic